Detailed Information

Cited 4 time in webofscience Cited 5 time in scopus
Metadata Downloads

Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial

Authors
Lee, Ji HyunPark, YongKang, Ka-WonLee, Je-JungLee, Ho SupEom, Hyeon-SeokDo, Young RokKim, Jin SeokYoon, Sung-SooShin, Dong-YeopKoh, YoungilKim, Ki-HyunLee, Won SikJo, Jae-CheolLee, Yoo JinLee, Ji YunKim, Dae SikShim, HyeokChang, Myung HeeKim, Sung-HyunMin, Chang-Ki
Issue Date
Aug-2021
Publisher
SPRINGER
Keywords
Carfilzomib; Lenalidomide; Relapsed and refractory multiple myeloma; Real-world; Asia
Citation
ANNALS OF HEMATOLOGY, v.100, no.8, pp 2051 - 2059
Pages
9
Indexed
SCIE
SCOPUS
Journal Title
ANNALS OF HEMATOLOGY
Volume
100
Number
8
Start Page
2051
End Page
2059
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/51676
DOI
10.1007/s00277-021-04407-0
ISSN
0939-5555
1432-0584
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five RRMM patients who were treated with carfilzomib in combination with Rd from the time of the first approval of KRd in the Republic of Korea were analyzed. The median age was 61 years. The percentage of patients with an ECOG performance status >= 3, creatinine clearance < 50 mL/min, high-risk cytogenetics, and >= 4 lines of prior treatment were 9%, 22%, 31%, and 27%, respectively. Forty-one patients started treatment with KRd, whereas the remaining 14 patients (25%) were added carfilzomib during the Rd treatment. In the whole cohort, the overall response rate was 73% and progression-free survival was 8.8 months. The addition of carfilzomib in patients who were refractory or had disease progression during Rd treatment reattained a response in half of the patients. The advantage of carfilzomib with Rd was significant in patients in the first relapse. Toxicity profile was acceptable, excluding severe infections. Carfilzomib in combination with Rd is effective and has a reasonable adverse event rate in Asian patients with RRMM.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Dae Sik photo

Kim, Dae Sik
Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE